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ABSTRACT
Background
Heart failure remains unexplored in sub-Saharan Africa. Comorbidities such as anemia and 
iron	deficiency	are	common	and	associated	with	increased	mortality.	Oral	iron	supplementa-
tion may be feasible in heart failure in countries with limited health care resources.
Objectives
1. To describe the contemporary etiology, clinical characteristics, prognosis and prognostic 
predictors in patients with heart failure in Tanzania.
2. To determine the prevalence, correlates and prognostic implications of anemia and iron 
deficiency	in	patients	with	heart	failure	in	Tanzania.
3. To compare patients with heart failure in Tanzania and Sweden, with regard to (1) clinical 
characteristics and utilization of heart failure therapy and (2) prognosis and its predictors.
4. To	determine	if	90	days	of	a	fixed-dose	oral	iron	sulphate	supplementation	on	top	of	stan-
dard	therapy	in	patients	with	heart	failure	and	iron	deficiency	results	in	an	improvement	
in serum ferritin and other hematological and cardiovascular parameters.
Study I
Etiology, clinical characteristics and prognosis in Tanzanian heart failure patients
The Tanzania heart failure (TaHeF) study was a prospective observational study conducted 
at Jakaya Kikwete Cardiac Centre of the Muhimbili National Hospital in Dar es Salaam, 
Tanzania.	Patients	≥18	years	of	age	with	heart	failure	defined	by	the	Framingham	criteria	
were included and the main outcome measure was all-cause mortality. The study comprised 
427 patients of whom 217 (51%) were females and the mean (standard deviation) age was 
55 (17) years. Heart failure etiologies included hypertension (45%), cardiomyopathy (28%), 
rheumatic heart disease (12%) and ischemic heart disease (9%). The mortality rate, 22.4/100 
person-years of observation over a median follow-up of 7 months, was independently 
associated	with	presence	of	atrial	fibrillation,	hazard	ratio	(HR)	3.4	(95%	confidence	interval	
[CI] 1.6-7.0); in-patient status, HR 3.2 (95% CI 1.5-6.8); anemia, HR 2.3 (95% CI 1.2-4.5); 
pulmonary hypertension, HR 2.1 (95% CI 1.1-4.2); creatinine clearance, HR 0.98 (95% CI 
0.97-1.00); and lack of formal education, HR 2.3 (95% CI 1.3-4.2).
Study II
Prevalence and prognostic implications of iron deficiency and anemia in heart failure 
in Tanzania
The design and patient material were the same as in study I. The main outcome measure was 
a composite of time to hospitalization for heart failure or death. The prevalence of anemia 
was	57%.	The	overall	prevalence	of	iron	deficiency	was	49%	distributed	as	69%	vs.	21%	in	
subjects with and without anemia (p<0.001). The one-year survival free from a composite of 
hospitalization	for	heart	failure	or	death	was	70%.	The	presence	of	iron	deficiency	anemia	
increased the likelihood for outcome measure (HR 2.67, 95% CI 1.4-5.1). Anemia without 
iron	deficiency	did	not	influence	the	risk.
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Study III
Characteristics and prognosis of patients with heart failure in Tanzania and Sweden
This was a prospective study in which the patients from the TaHeF study (Study I) were 
compared with patients from the Swedish heart failure registry (SwedeHF). Patients from 
TaHeF (n=427) and SwedeHF (n=51,060) were initially compared in unmatched cohorts. 
Another comparison was made after matching 1:3 by gender and age ±5 years (TaHeF 
n=411 vs. SwedeHF n=1232). The primary outcome was time to all-cause mortality. In the 
unmatched cohorts the TaHeF patients were younger (age [interquartile range; IQR] 55 [40-
68] vs. 77 [64-84] years; p<0.001) and more commonly women (51 vs. 40%; p<0.001). The 
three-year survival was 61% in both cohorts. In the matched cohorts, TaHeF patients had 
more hypertension (47 vs. 37%; p<0.001) and more anemia (57 vs. 9%; p<0.001). Their left 
ventricular ejection fraction (LVEF) was more frequently preserved and heart failure more 
advanced and of longer duration. Beta-blockers were less frequently used in Tanzania. The 
crude mortality was worse in TaHeF (HR 2.25, 95% CI 1.78-2.85; p<0.001) with a three-year 
survival of 61 vs. 83%. However, following multivariable adjustment, the risk was similar 
(HR 1.07, 95% CI 0.69-1.66; p=0.760). In both cohorts, preserved LVEF was associated with 
higher mortality than reduced LVEF in the crude but not in the adjusted analyses. 
Study IV
Oral iron improves serum ferritin in patients with heart failure and iron deficiency: A 
single-arm clinical trial within the Tanzania heart failure study
This	was	a	prospective,	single-arm	clinical	trial	which	included	patients	aged	≥18	years	with	
stable	symptomatic	(NYHA	II-IV)	heart	failure,	hemoglobin	8-15g/dl,	and	iron	deficiency,	
defined	as	serum	ferritin	 level	<100	ng/mL	or	100-299	ng/mL	with	concurrent	 transferrin	
saturation <20%. Oral ferrous sulphate was administered at dose of 200 mg three times per 
day during 90 days. A total of 237 patients were screened of whom 102 met inclusion criteria 
(54% males; mean age ± SD 58 ± 16 years). In 97 patients who completed follow-up, the 
mean (± SD) ferritin level improved from 123±70 ng/mL at baseline to 255±143 ng/mL 
after 90 days of treatment (+107%; p<0.001), hemoglobin from 11.7±2 to 12.3±2g/dL (+5%; 
p<0.001), 6MWT distance from 543±148 to 574±166 meters (+6%; p<0.001), LVEF from 
37.8±12.2 to 44.5±10.7% (+17%; p<0.001) and NT-proBNP from 986±774 to 582±503 ng/L 
(-41%; p<0.001).
Conclusions
Patients with heart failure in Tanzania were younger than their counterparts from the 
developed world. Hypertension was the leading cause of heart failure in Tanzania, unlike in 
Sweden and other developed countries where ischemic heart disease is predominant. This 
calls for the need for early detection and treatment of hypertension. Even after age and gender 
matching, patients in Tanzania had more severe heart failure and worse crude but similar 
adjusted	prognosis.	Independent	and	modifiable	predictors	of	mortality	were	anemia,	atrial	
fibrillation	and	lack	of	education.	Iron	deficiency	anemia,	common	in	Tanzanian	heart	failure	
patients, was independently associated with a poor prognosis. Oral iron supplementation was 
sufficiently	absorbed	to	replenish	serum	ferritin	in	Sub-Saharan	patients	with	heart	failure.	It	
was associated with improved hemoglobin, 6MWT distance, LVEF and NT-proBNP.
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INTRODUCTION
HEART FAILURE
Heart failure definition
The	 diagnostic	 criteria	 for	 heart	 failure	 are	 complex.	Traditionally	 the	 definition	 of	 heart	
failure	was	based	on	a	combination	of	symptoms	and	physical	signs	of	fluid	retention	as	e.g.	
in	 the	Framingham	Heart	Study	 criteria,	which	 are	100%	sensitive	 and	with	 a	 specificity	
of 78%1.	Due	 to	 advances	 in	diagnostic	 facilities,	 the	definition	of	 heart	 failure	has	been	
updated as can be seen in management guidelines issued by international cardiac societies. 
According to the European Society of Cardiology2,	the	diagnosis	requires	the	fulfillment	of	
three or more conditions (Table 1a). In this guideline, the term heart failure is used to describe 
the symptomatic syndrome, graded according to the New York Heart Association (NYHA) 
functional	classification	based	on	symptoms	and	signs	(Table	1b).
a.
The diagnosis of HF-REF requires three 
conditions to be satisfied:
1. Symptoms typical of HF
2. Signs typical of HF
3. Reduced LVEF
The diagnosis of HF-PEF requires four 
conditions to be satisfied:
1. Symptoms typical of HF
2. Signs typical of HF
3. Normal or only mildly reduced LVEF and 
LV not dilated
4. Relevant structural heart disease (LV 
hypertrophy/LA enlargement) and/or dias-
tolic dysfunction 
HF =  heart failure; HF-PEF = heart failure 
with ‘preserved’ ejection fraction;
HF-REF = heart failure and a reduced 
ejection fraction; LA = left atrial; LV = left
ventricular; LVEF = left ventricular ejection 
fraction. Signs may not be present in the 
early stages of HF (especially in HF-PEF) 
and in patients treated with diuretics.
b.
NYHA class Explanation
I No limitation of physical 
activity. Ordinary physical
activity does not cause un-
due breathlessness, fatigue,
or palpitations.
II Slight limitation of physical 
activity. Comfortable at
rest, but ordinary physical 
activity results in undue
breathlessness, fatigue, or 
palpitations.
III Marked limitation of phy-
sical activity. Comfortable at
rest, but less than ordinary 
physical activity results in
undue breathlessness, 
fatigue, or palpitations.
IV Unable to carry on any phy-
sical activity without
discomfort. Symptoms at 
rest can be present. If any
physical activity is 
undertaken, discomfort is 
increased.
Table 1.  Diagnosis of heart failure (a) and NYHA class based on symptoms and signs (b)
Abel Makubi
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Epidemiology
Heart failure is a worldwide public health problem that affects millions of people and 
carries a poor prognosis. The global prevalence of heart failure is estimated to be over 23 
million people3,4. The heart failure prevalence and incidence are 3% and 0.5% in developed 
countries, increasing with age1,3,5. The corresponding proportions in Sub-Saharan Africa are 
unknown. However, the available data based on hospital studies indicate that heart failure is 
the commonest cardiovascular condition and accounts for about 15-20% of deaths among 
Africans admitted to hospitals6,7. Heart failure is assumed to account for over 30% of 
admissions to cardiovascular units and 3-7% to general internal medicine wards in Africa8.
The pattern of cardiovascular disorders in Africa is becoming indistinguishable from those in 
developed countries9, with more people reaching middle and older ages as one explanation. 
Still in the few studies from Sub-Saharan Africa, the gender distribution appears equal but 
age is lower than in developed countries10–12.
Etiology
Large observational studies e.g. the Acute Decompensated Heart Failure National Registry 
(ADHERE) in the United States of America (USA) and Euro Heart Failure Survey II (EHFS 
II) in Europe have provided a greater insight into the etiology of patients with heart failure in 
developed countries 13,14. In these populations, ischemic heart failure alone or in coexistence 
with	hypertension,	atrial	fibrillation	and	diabetes	constitute	the	commonest	causes	of	heart	
failure, with dilated cardiomyopathy in a minority13,15. Despite this present understanding, the 
pattern of heart failure etiology is still evolving. The causes of heart failure and demographics 
are not uniformly distributed and great geographic variance exists. The picture seems more 
complex in Africa even if detailed information on this subject is limited. Historically, the 
main etiologies of heart failure in Sub-Saharan Africa have been rheumatic heart disease 
and cardiomyopathies16, but there may be a change towards a pattern more similar to that 
in the developed world12,17–19. The few available contemporary observational studies from 
Sub-Saharan Africa show that hypertension and idiopathic cardiomyopathies are main causes 
of	heart	failure	in	a	significantly	younger	group	of	patients	when		compared		to		those		in	
developed  countries19,20. Furthermore, myocardial infarction is becoming progressively more 
important with the adoption of western lifestyles and an ageing population21.
Therapy
During the past decades, clinical trials have provided valuable information of importance 
when managing heart failure patients22–25. Current guidelines advocate the use of angiotensin-
converting-enzyme inhibitors, angiotensin receptor blockers, mineralocorticoids receptor 
antagonists, diuretics and devices (implantable cardiac resynchroniation therapy and 
cardioverter-defibrillators)2,26. Still, evidence from developed countries shows that the 
adherence to the guideline recommendations, at least in some respects, is sub-optimal27–29. 
Little is known regarding the treatment practices of heart failure in Sub-Saharan Africa. 
The Sub-Saharan Africa Survey of heart failure (THESUS-HF) registry reported on three 
important observations regarding the management of heart failure. First the use of aspirin 
was frequent in patients with non-ischemic heart failure, while the combined use of the 
hydralazine and nitrate, shown to be effective in patients of African descent30, was hardly 
used at all, while beta-blockers were only prescribed to about 50% of heart failure patients20.
          Heart failure and anemia in Sub-Saharan Africa
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Prognosis
Despite available therapy, the prognosis of heart failure remains poor4,14,31. The Framingham 
study	suggested	that	the	one	and	five	year	survival	rates	were	a	remarkable	57%	and	25%	in	
men  and  64%  and  38% in  women32.  The ADHERE, EHFS II and the Organized Program 
to Initiate Lifesaving Treatment in Hospitalized Patients With heart failure (OPTIMIZE-
HF) registries showed an in-hospital mortality of 3.8-6.7%13,14,33. With regards to long-term 
outcomes, OPTIMIZE-HF reported 8.6% mortality after 90 days33. 
The limited data from Sub-Saharan Africa show a similar in-hospital mortality in the magnitude 
of 3.8% and 4.2% in the Nigerian acute heart failure and THESUS-HF registries20,34.The 
similarity in in-hospital mortality in reports from the developed countries and Africa is of 
interest  considering  the  demographic  and  etiological  differences between  these parts of 
the world.
ANEMIA
Anemia definition
The	World	Health	Organization	(WHO)	defines	anemia	as	hemoglobin	<13.0g/dl	in	men	and	
<12g/dl in women35 categorized as mild (hemoglobin 10-11.9 g/dl for women and 10-12.9 g/
dl for men), moderate (hemoglobin 7-9.9 g/dl for both genders) or severe (hemoglobin <7 g/
dl for both genders36 .
Anemia as an important comorbidity in heart failure
Evidence	 based	 therapy	management	 of	 heart	 failure	 remains	 difficult	 in	 the	 presence	 of	
comorbidities that contribute to the pathophysiology and progression of the underlying 
cardiac disease37,38.  Anemia, a frequent and important co-morbidity in refractory heart 
failure39, is potentially amenable to intervention40. 
The prevalence of anemia increases with worsening NYHA functional class and varies 
depending	on	the	studied	patient	population	and	the	hemoglobin	level	used	to	define	anemia.	
This explains why it ranges widely between 4% to 55% in various studies2,41,42 in developed 
countries. In the EHFS II43, which included 115 hospitals from 24 countries, 18% of male 
patients	were	anemic	(defined	as	a	hemoglobin	<11g/dl),		a	prevalence	that	would	have	been	
33% if the hemoglobin threshold had been increased to 12.0 g/dL. Thus, a 1.0 g/dL increase 
in the hemoglobin threshold nearly doubled the proportion of anemic patients in the same 
study cohort. 
The information on the presence of anemia in a Sub-Saharan Africa heart failure population is 
limited (Table 2) compared to the large number of studies of this topic performed in developed 
countries. Using the WHO cut-off, the scattered information reveals that the prevalence of 
anemia in heart failure in Sub-Saharan Africa ranges from 14-64% (average = 45%), to be 
compared with 36% in the general Sub-Saharan Africa population44.
Pathophysiology of anemia in heart failure                                                                                                                                          
The causes of anemia in heart failure are not well known. Anemia may be associated with 
iron,	 folate,	 or	 B12	 deficiency,	 renal	 failure	 or	 other	 comorbidities	 including	 anemia	 of	
chronic disease and dilutional anemia50.
Abel Makubi
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Iron deficiency
Iron is essential for cell growth, electron transport reactions, transport of oxygen, oxidative 
phosphorylation and for the function of some enzymes51.	Iron	deficiency	has	been	considered	
clinically	important	only	in	the	presence	of	anemia.	However,	iron	deficiency	impairs	aerobic	
performance regardless of the presence of anemia52, suggesting its role to be considerably 
more	complex.	Two	biochemical	forms	of	iron	deficiency	have	been	described.	The	first	is	
absolute	deficiency,	which	is	characterized	by	depletion	of	iron	available	in	the	circulation	
(bound to transferrin) and iron stores (ferritin in the liver and iron in the reticular endothelial 
system). This may be caused by poor dietary intake, chronic blood loss due to surgery, use of 
aspirin/non-steroidal	anti-inflammatory	drugs	leading	to	gastritis/peptic	ulcer	disease,	uremia,	
gastrointestinal malignancies or to increased iron demand as e.g. during pregnancy53,54. 
The	second	 form	 is	 functional	 iron	deficiency	 in	which	 there	 is	 a	depletion	of	 transferrin	
bound iron available in the circulation although the body storage of iron is adequate. This 
is	 partly	 due	 to	 blunted	 erythropoiesis	 induced	 by	 inflammation55 and  elevated hepcidin 
levels by sequestration of iron in macrophages, resulting in hypoferremia51. Hepcidin binds 
to the cellular iron export channel ferroportin causing its internalization and degradation 
thereby	decreasing	iron	efflux	from	iron	exporting	tissues	into	plasma.	By	this	mechanism,	
hepcidin	inhibits	dietary	iron	absorption,	the	efflux	of	recycled	iron	from	splenic	and	hepatic	
macrophages, and the release of iron from storage in hepatocytes51,56. With either of the two 
forms	of	iron	deficiency,	and	regardless	of	the	hemoglobin	level,	both	oxygen	delivery	and	
utilization are impaired in myocardial and other cells57,58.
Anemia of chronic disease
Anemia	is	often	associated	with	chronic	inflammatory	and	malignant	disorders,	as	well	as	
renal failure, and it has become increasingly recognized in heart failure. Cytokines such as 
tumor necrosis factor-alpha and interleukin-6 are elevated in heart failure and are associated 
Table 2. Studies in Sub-Saharan Africa in heart failure reporting anemia in adults
Authors, country and year Sample 
size
% Anemia
 
Definition of anemia by 
hemoglobin or packed cell 
volume
Ogah et al, Nigeria, 2014.34 452 8.8 <10g/dl
Damasceno et al, 9 African 
countries, 201212
1006 15.2 <10g/dl
Stewart et al, South Africa, 2008.19 699 10.0 Male, <11g/dl, female <10 g/dl 
Karaye et al, Nigeria, 2008. 45 79 41% Packed cell volume
<39% in male and 
<36% in female
Kuule et al, Uganda, 2009.36 157 64.3 Male, ≤12.9g/dl, 
female, ≤11.9g/dl
Inglis et al, South Africa, 2007.46 163 13.5 WHO
Dzudie et al, Cameroon, 2008. 140 15.7 Not available
Oyoo et al , Kenya, 1999.47 91 13.2 Not available
Ojji et al, Nigeria, 2013.48 475 8.0 Not available
Onwuchekwa et al,2009.49 423 6.2 Not available
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with the catabolic and dysmetabolic state seen late in the disease59. Increased erythrocyte 
sedimentation rate and levels of the acute phase reactants C-reactive protein (CRP) and 
ferritin are seen50,60. In patients with anemia and heart failure, iron can be absent in bone 
marrow	 stain,	 the	 gold	 standard	 for	 iron	 deficiency.	 However,	 in	 these	 patients,	 CRP	 is	
elevated	and	ferritin	is	not	suppressed,	as	would	be	expected	in	iron	deficiency,	suggesting	
that	inflammation	may	nevertheless	play	a	role61. Moreover, studies are ongoing to establish 
the exact role of hepcidin, a protein synthesized by the liver, which plays a major role in iron 
metabolism. Hepcidin synthesis is suppressed by anemia, hypoxia and erythropoiesis, and 
induced	by	inflammation56.	Inflammatory	cytokines,	such	as	interleukin-6	IL-6,	increase	the	
synthesis	of	hepcidin,	resulting	in	anemia	of	inflammation.	In	a	study	by	Matsumoto	et	al.62, 
serum hepcidin-25 concentrations were regulated by iron storage and erythropoiesis but not 
by	IL-6	in	heart	failure	patients	with	anemia	suggesting	that		that	anemia	of	inflammation	a	
minor cause of anemia in heart failure.
Use of angiotensin converting enzyme inhibitors
Angiotensin converting enzyme inhibitors may cause anemia and are indeed used to treat 
erythrocytosis. They reduce the hematocrit following renal transplantation and may induce 
or contribute to anemia in heart failure63.
The cardiorenal syndrome
Chronic and progressive renal failure and associated anemia is common in heart failure 
(Figure	1).	The	term	the	“cardiorenal	syndrome”	has	been	used,	but	a	clear	definition	does	
not exist. Renal failure in heart failure may be secondary to hypoperfusion and hypoxia, but 
also	 to	 venous	 congestion	 and	 inflammation.	 Impaired	 nutrition,	 decreased	 bone	marrow	
perfusion and side effects from heart failure drugs may also contribute to both renal failure 
and anemia64,65.
Figure 1. The cardiorenal anemia iron-deficiency syndrome may interact in a way that one 
exacerbates another
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Iron deficiency in heart failure
In	2002,	iron	deficiency	anemia	was	considered	to	be	among	the	most	important	contributing	
factors to the global burden of disease66. Surveys in Tanzania estimated that 30-55% of the 
adult population is anaemic67–69	and	the	prevalence	of	iron	deficiency	anemia	was	estimated	
to be 40-61%70–72.
Burden of iron deficiency in heart failure
In	developed	 countries	 the	prevalence	of	 iron	deficiency	 in	heart	 failure	 ranges	 from	14-
73% depending on the study population and which diagnostic criteria that are applied. 
Corresponding data in Sub-Saharan Africa are scarce (Table 3).
Diagnosis of iron deficiency in heart failure
Various studies have suggested higher levels (60-100 µg/L)83,84	of	serum	ferritin	as	sufficient	
for	diagnosing	absolute	iron	deficiency	in	the	presence	of	coexisting	inflammation,	infection	
and malignancy, as opposed to the more commonly used serum ferritin cut-off level of 
<30 µg/L83. Even stricter cut-off values, 12–15 µg/L, have been used85 in the absence of 
inflammation.	This	is	based	on	the	fact	 that	patients	with	acute	or	chronic	disease	usually	
have	elevated	levels	as	a	result	of	intracellular	iron	accumulation	and	inflammatory	response,	
serum ferritin being an active phase reactant. Therefore, in heart failure as with other chronic 
conditions,	iron	deficiency	has	been	defined	in	two	forms;	(1)	absolute	iron	deficiency	which	
is	defined	as	serum	ferritin	<100ng/ml	and	(2)	functional	iron	deficiency	defined	as	serum	
ferritin 100-300 ng/mL and transferrin saturation <20%61. These criteria have been used in 
several clinical trials in heart failure86–88.
Table 3. Studies reporting the magnitude of iron deficiency in heart failure
Authors, year N % With iron 
deficiency
Definition of iron deficiency
Jankowska et al, 2014.73 165 37 Low hepcidin and high sTfR
Serum ferritin and TSAT
Rangel et al, 2014.74 127 36 SF<100ug/L or SF 100-299ug/L +TSAT <20%       
Parikh et al, 2014.75 574 61 SF<100ug/L or SF 100-299ug/L +TSAT<20%       
Enjuanes et al, 2014.76 1278 58 SF<100ug/L or SF 100-299ug/L +TSAT<20%       
Ijsbrand  et al, 2014, 77 1506 50 SF <100ug/L or  SF 100-299ug/L +TSAT<20%     
Jankowska  et al, 2013,78 443 35 SF<100ug/L or  SF 100-300ug/L +TSAT<20%       
Nanas et al, 2006,61 37 73 Bone marrow
Cristina  et al, 2006,55 148 36 High soluble TR and /or low TSAT
Cohen-Solal A, et al 79 832 72 SF<100ug/L or SF 100-299ug/L +TSAT<20%       
Yeo TJ et al, 2014 80 751 61 SF<100ug/L or SF 100-299ug/L +TSAT<20%       
De Silva R et al, 2006. 81 955 29 Lower limit for serum iron and SF
Klaus K. A  et al, 2004.82 296 14 Low SF
Abbreviations. sTfR=Soluble transferrin receptor; TSAT=Transferrin saturation; SF=Serum ferritin; 
TR=Transferrin receptor.
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Prognostic role of iron deficiency in heart failure
There	is	limited	and	partially	conflicting	information	on	the	impact	of	iron	deficiency	on	
prognosis in heart failure. In most available studies74,76,77,89 iron	deficiency	carried	a	higher	
risk of poor outcome in heart failure irrespective of the presence of anemia. In contrast, 
Parikh et al75	found	that	iron	deficiency	was	not	associated	with	all	cause	or	cardiovascular	
mortality in patients with self-reported heart failure.
Intervention studies for iron deficiency in heart failure
Recombinant human erythropoietin
Several	 agents	 have	 been	 explored	 as	 potential	 therapies	 for	 iron	 deficiency	 in	 heart	
failure. Erythropoiesis stimulating agents such as recombinant human erythropoietin 
raise hemoglobin and improve functional and exercise capacity and quality of life in 
heart failure90, and in the Study of Anemia in heart failure Trial (STAMINA-HeFT) it 
was associated with a trend toward lower combined all-cause mortality and heart failure 
hospitalization91. However, these agents may be associated with adverse thromboembolic 
outcomes92,93.
Iron supplementation
Parenteral	 iron	 therapy	 has	 demonstrated	 short	 to	medium	 term	benefits	 in	 the	 form	of	
improved symptoms, quality of life measures and reduced hospitalization rates in a number 
of	controlled	and	uncontrolled	clinical	trials	in	heart	failure	and	iron	deficiency64,86,87,94–96 
(Table 4), all conducted in developed countries. In the Ferinject Assessment in Patients with 
Iron	Deficiency	and	Chronic	heart	failure	(FAIR-HF)	study86, patients were randomized to 
i.v. iron or placebo and 50% vs. 28% and 47% vs. 30% reported improved quality of life and 
NYHA class, respectively. Similarly in the Ferric Iron Sucrose in heart failure (FERRIC-
HF) study94, 35 patients with heart failure were subjected to 16 weeks of intravenous iron 
or no treatment in a 2:1 ratio. The NYHA functional class improved in 8 patients (44%) in 
the iron group versus none of the patients in the control group (p= 0.03). I.v. iron for heart 
failure has not been studied in Sub-Saharan Africa.
Oral	iron	is	an	established	therapy	for	treating	iron	deficiency	in	a	wide	range	of	medical	
conditions but has not yet been widely tested in heart failure. Preliminary studies on 
randomized clinical trial on erythropoietin stimulating agents vs. oral iron showed no 
iron improvement with oral therapy on hemoglobin, exercise and ferritin. However, in a 
recent, non-randomized clinical trial106 replenishment of hemoglobin, transferrin saturation 
(TSAT) and ferritin were similar to with i.v. iron in FAIR trial86 in patients with heart 
failure and preserved left ventricular ejection fraction.  A randomized trial107 also showed 
that ferritin and hemoglobin increased with both i.v. and oral iron.
CONCLUSIONS
Heart failure continues to remain a substantial burden on the health-care systems and 
communities in both developed and Sub-Saharan Africa countries. Despite the fact that a 
lot of progress has been made with regard to our understanding of the natural history of 
heart failure in developed countries, the picture is more complex in Sub-Saharan Africa 
and the limited data available have provided little insight on the etiology, comorbidities, 
treatment, and prognosis. 
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Anemia	and	iron	deficiency,	in	isolation	or	in	combination,	are	important	comorbidities	in	
heart failure and confer poor prognosis. Its treatment has been shown to improve the outcome 
in heart failure patients in developed countries. In Sub-Saharan Africa, the relation between 
anemia	and	iron	deficiency	remains	largely	unexplored	and	more	information	is	needed	to	
tackle this increasing public health problem for further development of locally feasible and 
acceptable interventions.
 
Table 4. Studies on intravenous iron in heart failure
Author and 
reference
Study design Sample 
size
Type of i.v. 
iron
Dose/duration Benefits
Ben-Assa et al, 
2015.97
Uncontrolled 34 Ferric sucrose 200 mg, 6w ↑hemoglobin
Reed et al, 2015.98 Uncontrolled 13 Ferric gluconate 250 mg bd/d, 3d ↑hemoglobin , ↑SF, 
↑TSAT
Gaber et al, 2011.99 Uncontrolled 40 Ferric dextran 200 mg/w, 4-8w ↑NYHA, ↑6MWD, 
↑SF,  ↑TSAT, ↑exercise 
capacity, ↑renal function, 
↑ QOL
Usmanov et al, 
2008.64
Uncontrolled 32 Ferric  sucrose 100 mg 3 
times/w, then 
once/w, 26w
↑hemoglobin, ↑NYHA,  
↑LV diameters 
Bolger et al,2006.100 Uncontrolled 16 Ferric sucrose 1 g daily, 12d ↑hemoglobin, ↑TSAT,  
↑6MWD ↑NYHA
Toblli et al , 2015.101 Controlled 60 Ferric sucrose 200 mg /w, 5w ↑hemoglobin, ↑SF, 
↑TSAT, ↑ LV diameters, 
↑LVEF, ↑ CrCl, ↑NT-
proBNP
Ponikowski et al, 
2014.87
Controlled 304 Ferric 
carboxymaltose
Total dose 500-
2000 mg, in 
correction phase 
and 500 mg in 
maintenance, 
52w
↑6MWD, ↑NYHA, 
exercise capacity, ↑PGA, 
↑QoL, ↓ heart failure 
hospitalization, ↑fatigue 
score 
Terrovitis et al, 
2012102 
Controlled 40 Ferric  sucrose 300 mg weekly, 
6w
↑hemoglobin
Anker et al, 2009.86 Controlled 459 Ferric 
carboxymaltose
200 mg, 24w ↑hemoglobin, ↑SF, 
↑TSAT, PGA, ↑NYHA, 
↑6MWD, trend  ↓heart 
failure hospitalization
Abbreviations: SF-Serum ferritin; TSAT=Transferrin saturation; NYHA=New York Heart Association; 6MWD=Six 
minute walk distance; QOL=Quality of life, LV=Left ventricular; LVEF=Left ventricular ejection fraction; 
PGA=patients’ global assessment, ↑=improved, ↓=worsened
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• To assess the contemporary etiology, clinical characteristics, prognosis and predictors of 
prognosis in heart failure in Tanzania.
• To	determine	the	prevalence	and	prognostic	implications	of	anemia	and	iron	deficiency	
in heart failure in Tanzania.
• To compare patients with heart failure in Tanzania and Sweden, with regard to (1) clinical 
characteristics and utilization of heart failure therapy, and (2) prognosis and prognostic 
indicators.
• To	 determine	 if	 90	 days	 of	 a	 fixed-dose	 oral	 iron	 sulphate	 supplementation	 on	 top	
of	 standard	 therapy	 in	 patients	 with	 heart	 failure	 and	 iron	 deficiency	 results	 in	 an	
improvement in serum ferritin and other hematological and cardiovascular variables.
AIMS
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STUDY METHODS
STUDY SETTINGS
The four studies were conducted at the Jakaya Kikwete Cardiac Institute (JKCI) of the 
Muhimbili National Hospital (MNH), in Dar es Salaam, Tanzania. This center is a national 
referral hospital serving all of Tanzania, close to 45 million people. In the third study, patients 
in TaHeF were compared to patients in the Swedish heart failure Registry (SwedeHF). Figure 
2 shows number of patients from the Tanzanian and Swedish cohorts in the different studies.
PARTICIPANTS, DESIGNS, PROTOCOLS AND ENDPOINTS
Study I
Aim
This study aimed to describe the contemporary etiology, clinical characteristics, mortality, 
and its predictors in heart failure in Tanzania.
Figure 2. Number of participants included in the four studies and their inter-relationships. 
The 411 patients in study III and 401 patients in Study II are subsets of the 427 in Study 
I. For study III, 411 TaHeF patients were age/gender matched to 1,232 patients from 
the SwedeHF and 427 TaHeF patients were compared to 51,060 patents from SwedeHF, 
without matching. TaHeF-ID included 102 patients with new inclusion criteria and new 
baseline assessments, and who were not necessarily part of TaHeF  
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Patients
The inclusion criterion in the Tanzania heart failure study (TaHeF) was a clinical diagnosis 
of heart failure according to the Framingham criteria. Following screening (n=521) in the 
outpatient clinic and among stable patients in inpatient cardiac wards 427 patients were 
recruited for the study. Exclusion criteria were age <18 years and declining to participate.
Study design and protocol
TaHeF was a prospective cohort study. At baseline, data from the patient history and physical 
examination	and	laboratory/imaging	studies	were	collected.	Descriptive	data	included	fifty	
demographic, social, heart failure clinical, co-morbidity, laboratory (MNH Central Pathology 
Laboratory) and echocardiography variables. The underlying probable cause of heart failure 
was clinically determined through a combination of case history, hospital records, physical 
examination, chest X-rays, ECG and echocardiographic recordings. Criteria for hypertensive 
heart	failure,	rheumatic	heart	disease,	and	cardiomyopathy	were	modified	according	to	the	
chronic heart failure cohort in the Heart of Soweto Study19,		according	to	definitions	listed	
in Table 5.
Endpoints
The outcome measure for study I was all-cause mortality. Patients were followed in the 
outpatient clinic on a monthly basis. Follow-up via clinic visits and phone contact were 
maintained until August 2013. Patients who could not be reached were censored alive at the 
last	confirmed	contact	or	considered	lost	to	follow-up	if	no	contact	was	made	after	enrollment.	
In patients who died outside of MNH, date of death was obtained from next of kin.
Table 5. Criteria for defining heart failure etiological conditions
Probable heart failure 
etiological condition
Criteria
Hypertensive heart 
failure
Clinical heart failure according to the Framingham criteria and documented 
history of Hypertension and at least one of the followings; increased LV, 
septal thickness (≥1.3 mm), diastolic dysfunction, LV systolic dysfunction
Ischemic heart failure Clinical heart failure according to the Framingham criteria and results 
of non-invasive (e.g. ECG and abnormal regional wall motion on 
echocardiography) or invasive tests when available (for purposes of TaHeF, 
performed abroad) with LV ejection fraction ≤45%
Heart failure due to 
idiopathic dilated 
cardiomyopathy
LV ejection fraction ≤45% and possibly LVEDD ≥55 mm of indeterminate 
origin 
Rheumatic heart 
failure
heart failure secondary to primary underlying rheumatic heart disease 
with moderate to severe cardiac valvular dysfunction (e.g. regurgitation 
or stenosis) 
Peripartum 
cardiomyopathy
Heart failure secondary to left ventricular systolic dysfunction (LV ejection 
fraction ≤45%) towards the end of pregnancy or in the months following 
delivery, where no other cause of heart failure is found. The left ventricle 
may not be dilated 
Other heart failure 
etiologies
Includes congenital heart disease with e.g. hypertrophic cardiomyopathy, 
restrictive cardiomyopathy, endomyocardial fibrosis, and heart failure 
secondary to HIV infection, tuberculosis or chronic lung disease
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Study II
Aim
To determine the prevalence, correlates and prognostic implications of anemia and iron 
deficiency	in	patients	with	heart	failure	in	Tanzania.
Patient selection
Patients in study 1 (n=427) were selected for study II with additional exclusion of those who 
were	lost	to	follow	up	or	lacked	information	on	hemoglobin.	The	final	population	consisted	
of 411 patients.
Study design and protocol.
This was the same as in study 1.
Dependent variables and endpoints
The primary dependent variable was anemia at baseline and the secondary dependent variable 
was a composite outcome of time to hospitalization for heart failure or all-cause mortality 
(whichever	 came	first).	The	 index	 date	was	 defined	 as	 date	 of	 outpatient	 visit	 or	 date	 of	
hospital.	Based	on	the	WHO	criteria,	anemia	was	defined	as	a	hemoglobin	<13	g/dl	for	males	
and <12 g/dl for females and graded as mild for levels between 10.0-12.9 g/dl (males)/11.9 
g/dl (females), moderate for a hemoglobin level between 7.0-9.9 g/dl and severe if <7 g/dl. 
Serum	iron	markers	were	not	available	and	iron	deficiency	was	therefore	defined	as	a	mean	
corpuscular	volume	(MCV)	of	<80	femtolitres	(fL)	[16].	Subsequently,	the	iron	deficiency	
and anemia status of each participant was allocated into one of the following four categories: 
1)	Anemia	no,	iron	deficiency	no	=	absence	of	anemia	+	MCV	≥80	fL;	2)	Anemia	no,	iron	
deficiency	yes	=	absence	of	anemia	+	MCV<80	fL;	3)	Anemia	yes,	 iron	deficiency	yes	=	
presence	of	anemia	+	MCV<80	 fL;	and	4)	Anemia	yes,	 iron	deficiency	no	=	presence	of	
anemia	+	MCV	≥80	fL
Study III
Aim 
To compare characteristics and prognosis of heart failure in TaHeF vs. SwedeHF.
Patients
Study III included the TaHeF patients in study I. SwedeHF provided the study population 
for comparison with regards to clinical characteristics, therapy, prognosis, and predictors of 
prognosis. This ongoing nationwide registry was initiated in 2000108. For the purpose of the 
present study, patients registered from May 11, 2000 to December 31, 2012 and followed 
until December 31, 2012 were included. 
Design and protocol
TaHeF and SwedeHF are both prospective cohorts where analyses for purposes of this 
comparison were conducted retrospectively. The SwedeHF protocol, case report form 
and annual reports are available at http//www.swedehf.se. Patients were compared overall 
(n=427 from TaHeF vs. 51,060 from SwedeHF) and after matching 1:3 by gender and age±5 
years yielding n=411 vs. n=1,232. All patients in TaHeF and SwedeHF were considered for 
matching except those who a) were lost to follow-up in TaHeF (n=16); and b) patients in both 
populations with missing echocardiographic information (n=18 and n=8,281, respectively).
          Heart failure and anemia in Sub-Saharan Africa
23
Endpoints
The	 index	date	was	 defined	 as	 the	 date	 of	 outpatient	 visit	 or	 date	 of	 hospital	 admission	 in	
TaHeF and hospital discharge in SwedeHF. The outcome was time from index date to all-
cause mortality. In TaHeF, patients were followed in the outpatient clinic on a monthly basis 
as in studies I and II. In SwedeHF date of death was obtained from the population registry and 
patients alive were censored at the time for the last follow-up, December 31 2012.
Study IV
Aim
The	aim	was	to	test	the	hypothesis	that	90	days	of	a	fixed-dose	oral	iron	sulphate	supplementation	
on	 top	 of	 standard	 therapy	 in	 patients	 with	 heart	 failure	 and	 iron	 deficiency	 results	 in	 an	
improvement in serum ferritin and other hematological and cardiovascular parameters.
Patients 
Study IV was conducted two years after TaHeF and included both surviving patients from 
TaHeF	and	new	heart	failure	patients	above	the	age	≥18	years.	Patients	were	required	to	have	
stable symptomatic (NYHA II-IV) heart failure (regardless of EF) based on symptoms and 
signs, at least one echocardiography abnormality from Table 1 and NT proBNP >300 ng/L, 
hemoglobin	8-15	g/dL	and	iron	deficiency	defined	as:	serum	ferritin	level	<100	μg/L	or 100-
299	μg/L	with	concurrent	transferrin	saturation	<20%.	Exclusion	criteria	were	age	<18	years;	
pregnant/lactating women; known stage III-IV liver disease; known stage III-IV HIV disease; 
known malignancy; evidence of active bleeding; known allergy or intolerance to iron tablets; 
already receiving or having an indication for iron supplementation; malabsorption condition 
or other condition other than heart failure suspected to interfere with iron absorption; having 
received blood transfusion in the last 4 weeks; known hemolytic anemia; known folate/B12 
deficiency;	and	consent	not	provided.	
Protocol
Following enrollment, all patients entered a three-month treatment period with open-label oral 
iron. During this period, patients were followed by monthly clinic visits. Iron therapy consisted 
of	oral	ferrous	sulphate	(film	coated	tablets)	at	dose	of	200	mg	administered	three	times	daily	
for three months. Criteria for early termination were: patient unable to tolerate treatment or 
developed an anaphylactic reaction. 
Endpoints
The primary outcome was the mean change in serum ferritin level from baseline to three 
months after oral iron initiation. Secondary outcomes included mean changes in hemoglobin, 
NT-proBNP, left ventricular ejection fraction (LVEF) and the six-minute walk test (6MWT) 
distance.
PROCEDURES AND LABORATORY TESTS
Echocardiography
For all studies for Tanzanian patients, echocardiography was performed with General Electric 
Vivid 5 with a 2.5-5 MHz probe. LVEF was measured by the 2D Biplane Simpson technique 
and agreed by consensus between two senior cardiologists at MNH. In SwedeHF, LVEF was 
determined according to local protocol at each participating site.
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Hematological measurements
For	all	studies	at	MNH	full	blood	profiles	were	obtained	by	means	of	a	hematology	analyzer	
(Beckman	Coulter	ACT5	DIFF).	In	SwedeHF	the	corresponding	profiles	were	performed	at	
local accredited laboratories.
Biochemical analyses
Blood samples for all biochemical tests were drawn from an antecubital vein, collected in two 
tubes (a total of 10 ml) that immediately were put in ice and centrifuged within 20 minutes. 
Biochemical tests (serum ferritin, serum iron, transferrin saturation and creatinine were 
performed using Cobas Integra 400 Plus Chemistry Analyzer (Roche, Basel, Switzerland) 
while creatinine was analyzed by the use of a Chemistry Analyzer (Roche Cobas Integra 400 
plus) at the National Central Pathology Laboratory at MNH. Serum NT-proBNP levels were 
analyzed at the central pathology laboratory of MNH with enzyme immunoassay for the 
quantitative determination (Biomedica Medizinprodukte GmbH & Co KG, Vienna, Austria) 
using BIOTEC ELISA Reader (ELx800). In SwedeHF laboratory data were analysed 
according to accredited methods at local participating sites.
Six-Minute walk test
In study IV 6MWT was conducted by a single operator in a 30 m marked indoor corridor, 
following the American Thoracic Society guidelines (10). The Borg scale was recorded at 
baseline and six minutes. 
All investigations performed at baseline (except ECG) were repeated at the three-month 
follow-up visit in study IV. Moreover, all investigator-judged adverse events during the three-
month follow-up period were recorded. Patients were also urged to report possible adverse 
effects of iron replacement, such as abdominal cramps, constipation, heartburn, nausea, and 
vomiting, which were also recorded.
STATISTICAL METHODS
Descriptive statistics
Data in TaHeF were entered into an electronic case report form built in the OpenClinica 
software (https://www.openclinica.com/) and via a web-based case report form (eCRF) into 
a database managed by the Uppsala Clinical Research Center (UCR, Uppsala, Sweden) 
in SwedeHF. Continuous variables were tested for normality distribution using normal 
probability plots and reported as mean ± standard deviation or median (interquartile range) 
if data distribution was skewed. Categorical variables were summarized using frequencies 
and	percentages.	The	influence	of	selected,	clinically	relevant	characteristics	on	outcomes	
was assessed by Kaplan-Meier plots. Analyses were performed using stata version 13 and 
R	statistical	packages.	A	two-sided	p-value	of	0.05	was	considered	statistically	significant.
Analytical statistics
Study I
Univariate and multivariate Cox proportional hazards regression analyses were used to 
assess the association between baseline variables and mortality during follow-up. Criteria 
for entry into the multivariate model were clinical relevance (age and gender) or p-value 
≤0.10	in	univariate	analysis.	Patients	who	were	lost	to	follow-up	(16	of	427)	were	excluded	
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from survival analyses and patients who had missing data (57 of 411 patients on follow-up) 
were excluded from multivariate analysis, leaving 354 patients included in the multivariate 
analysis.
Study II
The association between selected baseline characteristics and survival free from a composite 
of hospitalization due to heart failure or all-cause mortality was assessed by Kaplan-Meier 
plots. Univariate and multivariate logistic regression analyses were used to determine the 
association between baseline variables and presence of anemia at baseline as a dichotomous 
variable, while Cox regression was used to determine the association between anemia and iron 
deficiency	and	the	composite	endpoint.	In	the	multivariate	analysis	all	variables	with	p-value	
<0.10, and in addition age, sex and heart failure causes, were included. Additional restricted 
cubic spline models at three knots were used to determine the linear effect quantitative 
variables on primary and secondary outcomes. Patients who were lost to follow-up (16 of 
401) were excluded from the analyses of the composite outcome. Analyses were adjusted for 
potential	modification	effects	of	sex,	LVEF,	site	of	recruitment	and	NYHA	class.	Interaction	
terms	between	exposure	categories	and	potential	effect	modifiers	were	created	and	assessed	
for	 significance	 in	 the	multivariate	models	 using	 a	 likelihood	 ratio	 test,	 estimates	 of	 the	
associations	being	stratified	by	the	variable	of	interest.
Study III
For baseline description of clinical characteristics, continuous variables were reported as 
median (interquartile range) and compared using Mann-Whitney U-test while categorical 
variables were compared by means of the chi-square test. The risk of heart failure in TaHeF 
vs.	in	SwedeHF,	overall	and	by	heart	failure	with	preserved	EF	(HFpEF;	defined	as	EF	≥40%)	
and	reduced	EF	(HFrEF;	defined	as	LVEF	<40%),	was	assessed	in	Kaplan-Meier	analyses	
and univariable Cox regressions. Adjustment for clinically relevant confounders was made 
by multivariable Cox regressions. The interaction between cohort and selected clinically 
relevant	 baseline	 pre-defined	 sub-groups	 and	 the	 hazard	 ratios	 in	 these	 sub-groups	 were	
assessed in multivariable Cox regressions and displayed in a forest plot. Furthermore, the 
association between selected baseline variables and mortality was assessed by multivariable 
Cox regressions separately in the matched TaHeF and SwedeHF populations. Missing data 
was handled by multiple imputations (n=10), imputed separately in the SwedeHF and TaHeF 
populations.
Study IV
The sample size calculation was based on a 100% increase from baseline in mean serum 
ferritin based on Beck-da-Silva et al 107. A minimum of 89 patients would be required to reach 
this increase with a standard deviation of the mean differences of 250 ng/mL, using a 2-sided 
alpha of 0.05 with 90% power. Considering a possibility of 15% dropout rate, the sample 
size was set to 102. Paired analyses with the use of t-test or Wilcoxon matched pairs test 
where appropriate were performed on primary and secondary measures before and after iron 
supplementation.	Pre-specified	subgroup	analyses	of	the	primary	endpoint	were	performed	in	
relation	to:	NYHA	class,	presence	or	absence	of	anemia	based	on	the	WHO	definition	109 and 
heart	failure	with	preserved	EF	(HFpEF;	defined	as	EF	≥40%)	vs.	heart	failure	with	reduced	
EF	(HFrEF;	defined	as	LVEF	<40%)110. The relation between the baseline serum ferritin and 
percentage change in ferritin concentration was assessed using linear regression.
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ETHICAL CONSIDERATIONS
All studies conformed to the declaration of Helsinki. The TaHeF study was approved by the 
ethical review board of the Muhimbili University of Health and Allied Sciences (MUHAS). 
Permission to conduct the study was obtained from MNH. All patients provided written 
informed consent. The establishment of the SwedeHF registry was approved by a multisite 
Ethics Committee. Individual patient consent was not required, but the patients were informed 
of entry into national registries and allowed to opt out. Permission to access data for the 
purpose of study III was provided by the SwedeHF steering committee and a separate ethics 
approval was obtained for this study within SwedeHF.
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RESULTS
Selected baseline clinical characteristics for participants included in TaHeF studies I-III are 
presented in Table 6, which also includes the corresponding comparison population from 
SwedeHF for study III.
STUDY I 
Among 427 included patients in TaHeF (Table 6 and Figure 2), 217 (51%) were females 
and the mean (standard deviation) age was 55 (17) years. A majority of patients had formal 
education (80%), were outpatients (63%) and were either in NYHA class III or IV (71%).
Etiologies of heart failure
Among 388 patients who had echocardiography examination, heart failure etiologies included 
hypertension (45%), cardiomyopathy (28%), rheumatic heart disease (12%), ischemic heart 
disease (9%), TB related pericardial disease (2%), HIV related cardiomyopathy (1%) and 
endomyocardial	fibrosis	(0.5%)	(Figure	3).	
Comorbidities in heart failure 
Pulmonary	hypertension	(Pulmonary	HT)	was	present	in	17%	of	patients,	atrial	fibrillation	in	
16%,	diabetes	in	12%,	and	clinically	significant	anemia	in	12%	(Figure	4).	Mean	LVEF	was	
41 ± 12% and 62% of patients had an LVEF <45%. 
Prognosis and its predictors
During follow up, 66 patients died, resulting in a mortality rate of 22.4 per 100 person-years 
of observation. The overall six-month survival rate was 90%.
The	multivariate	predictors	of	mortality	(Figure	5)	were	atrial	fibrillation,	hazard	ratio	3.4	
(95%	confidence	interval	1.6	to	7.0);	in-patient	status	3.2	(1.5	to	6.8);	anemia,	2.3	(1.2	to	4.5);	
pulmonary hypertension, 2.1 (1.1 to 4.2); lower creatinine clearance, 0.98 per unit increase 
(0.97 to 1.00) and lack of formal education, 2.3 (1.3 to 4.2).
STUDY II
A total of 401 heart failure patients (Figure 2) (median age 56 [IQR 41-67]) years were 
included.  Selected baseline characteristics are presented in Table 6.
Prevalence of anemia and iron deficiency
The	prevalence	of	anemia	was	57%	(Figure	6).	The	prevalence	of	iron	deficiency	was	49%	
distributed as 69% vs. 21% in subjects with and without anemia (p-value <0.001). Normocytic 
anemia was observed in 18% of the patients while none had macrocytic anemia.
Factors associated with anemia in heart failure
The risk of having anemia was positively associated with residency outside Dar es Salaam 
(OR	1.72;	[95%	CI	1.02	–	2.89];	p=0.038),	atrial	fibrillation	(4.12	[1.60	–	10.61];	p=0.003),	
LVEF <45% (2.70 [1.57 – 4.67]; p<0.001) and negatively (ORs per unit decrease) with 
creatinine clearance (0.98 per unit increase [0.97 – 0.99]; p=0.012) and total cholesterol (0.78 
per unit increase; [0.63 – 0.98]; p=0.029).
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Table 6. Baseline characteristics of study participants
Continuous variables are presented as median (interquartile range [IQR]) and categorical variables as 
numbers (%) if not otherwise stated
Variable TaHeF
Study I
TaHeF
Study II
SwedeHF
Study III
n=427 n=401 n=51,060 n=1,232
Unmatched
Compared
vs.TaHeF_study_I 
(n=427)
Matched
Compared
vs.TaHeF
 (n=411)
n/median %/IQR n/median %/IQR n/median %/IQR n/median %/IQR
Social demographics
Age (years) 55 41-68 55 41-67 77 68-84 55 41-67
Males 210 49 30,871 60 612 50
Formal education 337 80 318 79 51,060 100 1,232 100
Clinical 
In-patient 117 27 112 30 30,665 60 581 47
Heart failure duration 
≥6months
287 67 70 67 25,491 50 478 39
NYHA class III-IV 342 79 320 80 14,882 43 308 32
Pharmacological treatment 
ACEi/ARB 393 92 393 92 40,691 80 1,110 90
Beta blockers 177 42 177 41 42,352 84 1,088 89
Loop diuretics 374 88 350 82 40,926 81 811 66
Aldosterone antagonist 308 72 308 72 14,258 28 357 29
Digoxin 165 39 165 39 8,795 71 187 15
Hydralazine 19 4 19 4
Statins 33 8 33 8 21,683 42
Aspirin 109 26 109 26
Clopidogrel 21 5 21 5
Antiretroviral therapy 10 2 10 3
Warfarin 11 3 11 3 18,408 36 406 33
History of invasive 
treatment
Valve intervention 2,787 6 69 6
Revascularised 12,277 24
Cardiac resynchronisation 
therapy
1,014 20
Implantable cardioverter 
defibrillator
1,278 26
Physical examination
Body mass index (kg/m2)
<20 19 4 17 4 2,666 12 63 10
20-25 208 49 197 49 8,186 38 203 32
26-30 119 27 110 27 5,784 27 182 29
>30 81 20 77 19 5,175 24 187 29
Heart rate (beats/min) 88 72-104 88 73-104 72 64-83
Blood pressure (mmHg)
 Systolic 132 28 132 28 127 110-140 120 109-
135
 Diastolic 84 16 84 16 70 65-80 73 65-80
LV ejection fraction (%) 40 32-48 40 32-47
Creatinine clearance 
(ml/min)
68 49-89 67 48-89 56 39-81
Hemoglobin (g/L) 119 106-
132
119 106-
132
132 119-144
NT-proBNP (ng/L) 2,651 1,130-
5,870
Abbreviations. NYHA=New York Heart Association; ACEi= An angiotensin-converting-enzyme inhibitor; 
ARB=Angiotensin receptor blocker; NT-proBNP=N-terminal pro B-type natriuretic peptide.
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Figure 3. Etiologies of heart failure in TaHeF
Others, hypertrophic cardiomyopathy (0.7%); restrictive cardiomyopathy (0.5%); and adult congenital 
disease (0.3%); HD, heart disease.
Figure 4. Prevalence of comorbidities in heart failure 
COPD-chronic obstructive pulmonary disease, HT-hypertension, DVT-deep venous thrombosis
Figure 5. Predictors of mortality in heart failure in TaHeF 
Abbreviations. CV=Cardiovascular, NYHA=New York Heart Association; MAP=Mean arterial pressure; 
BMI=Body Mass Index; EF-Ejection fraction.
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Prognostic associations between of iron deficiency, anemia, and the composite endpoint
The one-year survival free from a composite of hospitalization for heart failure or death 
from any cause was 70%. After adjustment of a number of confounders, the presence of iron 
deficiency	anemia	increased	the	risk	(HR	2.67;	95%	CI	1.39	–	5.07;	p=0.003),	while	anemia	
without	iron	deficiency	or	iron	deficiency	without	anemia	did	not	influence	the	risk.
STUDY III
Patients included for the overall unmatched comparison of TaHeF (n=427) vs. SwedeHF 
(n=51,060) and for the matched cohorts of TaHeF (n=411) vs. SwedeHF (n=1232) are shown 
in Figure 2. Selected baseline characteristics for unmatched and matched SwedeHF cohorts 
are presented in Table 6.
Fifty one per cent of TaHeF patients were women and median age was 55 ([IQR] 40-69) year 
while a majority of the Swedish patients were men (60%; p<0.001) and the median age was 
significantly	higher	than	in	TaHeF,	at	77	(64-84)	years	(p<0.001).	
Unmatched cohorts
There were, as expected, numerous demographic and clinical differences in both the overall 
and matched cohorts. TaHeF patients had a lower level of the following: education, LVEF, 
body	mass	index	(BMI)	(Table	6),	prevalence	of	 ischemic	heart	disease,	atrial	fibrillation,	
diabetes mellitus and pulmonary disease. The prevalence of hypertension was similar while 
NYHA class was more advanced and the prevalence of anemia was higher while the use 
of beta-blockers was lower in the TaHeF population in which there was no use of revascu-
larization,	cardiac	 resynchronization	 therapy	 (CRT)	or	 implantable	cardioverter	defibrilla-
tor (ICD). Despite the much higher age in SwedeHF, the survival up to 3 years was only 
minimally greater in TaHeF and at three years, it was similar at 61% in both overall cohorts 
(Figure 7).
Figure 6. Prevalence of anemia in relation to microcytosis (MCV<80fl) and hypochromia 
(mean corpuscular hemoglobin <27pg).
          Heart failure and anemia in Sub-Saharan Africa
31
Matched cohorts
TaHeF patients had more hypertension (47% vs. 37%, p<0.001), more anemia (57% vs. 9%), 
more preserved LVEF, more advanced heart failure, longer duration of heart failure, while the 
proportion	of	ischemic	heart	disease,	diabetes	and	atrial	fibrillation	were	higher	in	SwedeHF	
(all, p<0.001) (Figure 8). 
The three year survival rates were 83% (95% CI 80-85%) in SwedeHF vs. 61% (95%CI 54-
67%) in TaHeF (p<0.001; Figure 9).
Figure 7. Kaplan-Meir curves for overall survival in the TaHeF and SwedeHF un-matched 
populations
Figure 8. Risk factors and comorbidities in the matched TaHeF and SwedeHF Cohorts
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Survival did not differ between HFpEF vs. HFrEF in either cohort (HFpEF vs. HFrEF 
p=0.550; SwedeHF HFpEF vs. HFrEF p=0.108). As in the overall population, survival in 
the matched population was worse in TaHeF than in SwedeHF (both in HFpEF and HFrEF 
p<0.001; HFrEF p<0.001; Figure 10).
Figure 9. Kaplan-Meir curves for overall survival in the TaHeF and SwedeHF matched 
populations
Figure 10. Kaplan-Meir curves for survival in the TaHeF and SwedeHF matched populations 
according to preserved (pEF) vs. reduced ejection fraction (reF)
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Comparative prognosis and predictors of prognosis
In the matched cohort, the unadjusted risk of mortality was greater in TaHeF (HR 2.25 
[95% CI 1.78-2.85], p<0.001), with three-year survival 61% vs. 83%. However, covariate-
adjusted risk was similar (HR 1.07, 95% CI 0.69-1.66; p=0.760). In both cohorts, HFpEF was 
associated with higher mortality in crude but not adjusted analysis and variables associated 
with greater adjusted mortality included higher age and NYHA class (Table 7).
Table 7. Crude and adjusted risk of mortality in TaHeF vs. SwedeHF by Cox regression.
TaHeF vs. SwedeHF*
Events/person-years 115/758 vs. 234/3995
Hazard ratio (95% CI) p-value
Crude 2.25 (1.78-2.85) <0.001
Multivariable model** 1.07 (0.69-1.66) 0.760
Adjusted for each of the following:
NYHA class (2 categories)α 1.51 (1.17-1.95) 0.001
LVEF (4 categories)¥ 2.17 (1.71-2.77) <0.001
Caregiver unit (2 categories)β 2.64 (2.07-3.37) <0.001
All 3 above (NYHA/LVEF/caregiver) 1.56 (1.17-2.06) 0.002
Educational level 1.96 (1.52-2.52) <0.001
Duration of heart failure 1.95 (1.53-2.48) <0.001
Ischaemic heart disease 2.69 (2.10-3.44) <0.001
Hypertension 2.22 (1.75-2.81) <0.001
Atrial fibrillation/flutter 2.71 (2.13-3.46) <0.001
RAS 2.28 (1.80-2.88) <0.001
Beta-blockers 2.02 (1.52-2.69) <0.001
Aldosterone antagonist 1.93 (1.49-2.49) <0.001
All 3 above (RAS/BB/Aldo) 1.78 (1.32-2.41) <0.001
Heart rate 1.98 (1.53-2.55) <0.001
Systolic blood pressure 2.31 (1.82-2.94) <0.001
Body mass index (continuous, using 
restricted cubic splines)
2.06 (1.62-2.63) <0.001
Creatinine clearance (continuous, using 
restricted cubic splines)
1.45 (1.14-1.85) 0.003
NYHA + creatinine clearance 1.08 (0.83-1.39) 0.585
*Reference category
**Model was adjusted for NYHA, LVEF, heart failure duration, In/out-patient, Education, Smoking, 
Creatinine clearance, Systolic blood pressure, Heart rate, Body mass index, Ischemic heart disease, 
Atrial fib/flutter, Hypertension, Anemia, Diabetes, Lung disease, Calcific valve disease, RAS, Beta-
blockers, aldosterone antagonist, Digoxin, Diuretics = 22 variables. (2 categories)α= I-II vs. III-IV, (4 
categories)¥= LVEF<30 vs. 30-39,40-49, ≥50, (2 categories)β= Outpatient vs. inpatient
CI = confidence interval
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STUDY IV
Figure	11	shows	the	flow	of	patients	screened	(n=237),	included	(n=102)	and	with	completed	
follow-up (n=97). 
Fifty-five	patients	(54%)	were	male	and	the	mean	age±SD	58±16	years.	A	majority	of	the	
patients had primary school education (54%). The heart failure etiology was hypertensive 
in 48%, dilated cardiomyopathy in 26%, ischemic in 15% and rheumatic heart disease in 
7%. Renin angiotensin system antagonists, beta-blockers and mineralocorticoid receptor 
antagonists were used in 85%, 74% and 87% of the patients respectively.
Primary endpoint
Five of the 102 patients did not complete 90 days of follow-up; out of these, 2 were intolerant 
to iron, 2 withdrew and 1 died. Thus 97 patients completed the study and were available for 
both baseline and follow-up assessment.
In the 97 patients, the ferritin level was 123±70 ng/mL at baseline and 255±143 ng/mL at 
day 90, a mean increase of 132±118 ng/mL (primary endpoint; +107%; P<0.001; Figure 
12A). Numerous secondary endpoint parameters also demonstrated improvement. The 
corresponding values for TSAT were 10±12% at baseline and 25±10% after 90 days (+150%; 
p<0.001); transferrin 2.9±0.6g/L to 2.6±0.5g/L (-10%; p<0.001; Figure 12 B and C). 
Primary and secondary endpoints
Secondary outcomes and other variables before and after oral iron are shown in Table 8.
Figure 11. Flow chart of patient inclusion and exclusion in TaHeF-iron deficiency (Study IV)
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Figure 12 A-C. Mean change in serum Ferritin levels and related iron markers between day 
0 and day 90  
Table 8. Secondary outcomes and other variables before and after oral iron (n=97). 
Measure Baseline Day 90 Change p-value
Secondary endpoints Mean±SD Mean±SD Mean±SD %
   Hemoglobin (g/dL) 11.7±2.0 12.3±1.8 0.6±1.4 5 <0.001
   Creatinine clearance (mL/min) 61.2±27.9 63.8±33.2 2.6±18.7 4 0.1788
   NT-proBNP (ng/L) 986.8±774.4 582.2±503.2 -404.7±452.6 -41 <0.001
   LV ejection fraction (%) 37.8±12.2 44.5±10.7 6.6±9.8 17 <0.001
   6MWT distance (meters) 543±148 574±166 31±67 6 <0.001
Other variables
  Serum iron (umol/L) 10.5±4.7 15.6±5.7 5.1±6.8 49 <0.001
  Transferrin (g/L) 2.9±0.6 2.6±0.5 -0.3±0.6 -10 <0.001
  White blood cells(x109/L) 6.2±3.0 6.1±2.1 -0.06±2.7 -0.9 0.826
  Mean corpuscular volume (fl) 84.9±11.8 86.5±9.4 1.5±11.5 2 0.021
  Mean corpuscular hemoglobin(pg) 27.5±4.4 29.2±3.0 1.7±3.4 6 <0.001
  Mean corpuscular hemoglobin 
  concentration (g/dL)
31.5±2.6 32.82±2.9 1.2±3.2 1 <0.001
  Red cell distribution width (%) 17.5±3.7 15.9±2.5 -1.6±3.4 -9 <0.001
  Platelets (nox109/L) 215.6±88.2 216.6±81.2 1.3±71.8 0.6 0.861
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GENERAL  DISCUSSION
Although there are previous studies of cardiovascular disease and heart failure in Sub-Saharan 
Africa17,19,20,34,111,112, we believe the data presented in Studies I-IV are the most clinically 
detailed,	up-to-date	and	comprehensive.	In	addition,	Study	III	provides	the	first	patient-level	
comparison between heart failure patients in a Sub-Saharan and a developed country.
The	main	findings	in	this	thesis	are	1)	in	Tanzania,	as	representative	of	Sub-Saharan	Africa,	
heart failure patients are young with hypertension a major driving force and with anemia, iron 
deficiency	and	atrial	fibrillation	not	treated	with	anticoagulation	as	common	co-morbidities	
that are also associated with an impaired prognosis; 2) In heart failure in Tanzania, survival 
is worse compared to in Sweden, as representative of a developed country. However, 
after adjustment for the greater severity of heart failure in Tanzania and other differences 
between TaHeF and SwedeHF, the prognosis was similar; 3) oral iron supplementation was 
sufficiently	absorbed	to	replenish	iron	stores	in	sub-Saharan	patients	with	heart	failure	and	
iron	deficiency.	Accordingly,	the	present	findings	open	for	targeted	public	health	interventions	
with the intention to impact the incidence and prognosis of heart failure in Tanzania and 
reasonably even other Sub-Saharan heart failure populations.
Demographics in heart failure
The	 findings	 that	 heart	 failure	 patients	 in	Tanzania	 are	 younger	 than	 those	 in	 developed	
countries is of public health and societal importance as it impacts on an economically and 
a socially productive population. These patients are, in contrast to a majority of those in the 
developed world, in a productive age and may be caring for children. The TaHeF study along 
with a handful of other registries or cohort studies12,19,34 added to the volume of knowledge 
regarding heart failure demographics in Sub-Saharan Africa. The mean age of patients with 
heart failure in the USA and Europe is between 70-73 years113,114. This contrasts greatly with 
the	current	findings	and	other	studies	in	Sub-Saharan	Africa,	where	the	patients	are	between	
the ages of 42-59 years12,19,34. One possible explanation for this difference is that hypertension, 
which according to Study I was an important main cause of heart failure in Tanzania, tends 
to affect patients already at a young and middle age 115. In addition, they may have a more 
accelerated disease course more rapidly leading to end organ damage21. The disparity might 
also be explained by differences in life expectancy, which in 2014 averaged 63 years in 
Tanzania, 79 years in the US and 82 years in Sweden116.
In TaHeF, heart failure was almost equally distributed among males and females, consistent 
with the THESUS-HF. THESUS-HF was an observational survey of patients admitted with 
acute heart failure in nine countries of Sub-Saharan Africa whose goal was to describe causes, 
treatment and outcomes in heart failure12. In the EHFS II, a study that examined clinical 
characteristics, etiology, treatment, and outcome of acute heart failure in Europe, patients 
were more commonly male (61%)117. Females were generally older than males in most of 
heart failure registries in developed countries117,118, contrary to in TaHeF and THESUS-HF, 
in which males were slightly older. This might be explained by a higher life expectance in 
females (84 years) than in males (80 years) in developed countries119, but the reasons why in 
Tanzania, male heart failure patients are older than female heart failure patients are less clear.
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Etiologies of heart failure
TaHeF revealed that hypertension is a major etiological factor behind heart failure which is 
a striking temporal change in the historical pattern of heart failure in Tanzania and contrasts 
the dominant role of ischemic heart disease in developed economies120,121.	This	finding	 in	
TaHeF outdates the previous predominance of rheumatic heart disease and cardiomyopathy 
as the major contributors to heart failure in Sub-Saharan Africa122,123	extending	the	findings	
from THESUS-HF12,19 and the Heart of Soweto Study Cohort19. Even after matching for age 
and in comparison to SwedeHF, the high rate of hypertension was consistent, calling for 
targeted and ambitious public health interventions to reduce the incidence of heart failure 
and possibly other complications of hypertension such as stroke, myocardial infarction and 
kidney disease. Several reports from Sub-Saharan Africa11,12,19 have emphasized hypertension 
as an increasingly important contributor to heart failure and other cardiovascular syndromes. 
These	 findings	may	 reflect	 an	 ethnic	 characteristic	 with	 a	 genetic	 predisposition	 both	 to	
hypertension and to the adverse sequele of hypertension potentially at an earlier stage than 
in Europeans11,21,111. The higher rate of underdiagnosed, untreated, and inadequately treated 
hypertension in Sub-Saharan Africa than in developed countries might also explain this 
predominance of hypertension as a main risk factor in heart failure. Such risk may explain 
the considerably worse renal function that we observed in TaHeF and should encourage to 
early detection and target driven treatment according to available guidelines124.	Modifiable	
factors such as smoking, diet, and sedentary lifestyle, as well as under-diagnosis and under-
treatment of hypertension, can be targeted at low cost and complexity.
The diminishing role of rheumatic heart disease and persistence of dilated cardiomyopathies 
(i.e.	idiopathic	and	postpartum)	in	the	TaHeF	are	consistent	with	findings	from	other	Sub-
Saharan Africa cohorts12,34. Rheumatic heart disease is becoming less common in Sub-
Saharan Africa in adults because of widespread use of antibiotics for group A streptococcal 
pharyngitis. Establishment of a national preventive program could possibly lead to further 
reductions of this condition, approaching the very low levels seen in developed countries.
Clinical presentation and comorbidities in heart failure
In	the	TaHeF	study,	patients	presented	late	in	the	course	of	heart	failure.	This	was	reflected	
by	findings	from	the	matched	TaHeF	and	SwedeHF	cohorts,	in	which	patients	in	Tanzania	
had	clinically	more	severe	heart	 failure	by	NYHA	classification	and	worse	 renal	 function	
than those in Sweden. This may be attributed to patient delay and/or poor and/or later access 
to care. Even if access to care were adequate in Tanzania, the higher level of education in 
developed countries may be associated with higher health literacy and propensity to seek care 
than in Tanzania.
Anemia was common in heart failure despite the fact that a majority of patients were rela-
tively young (median age 56 years), in a stable condition (49% in NYHA III as compared 
to	31%	in	NYHA	IV)	and	ambulatory	status	(70%	outpatients).	The	current	findings	(57%	
prevalence of anaemia) are about the same as in a similar study from Uganda36 but in both 
this and the present study, the proportion was higher than in some other Sub-Saharan Africa 
countries (13-41%)45,46. Compared to developed countries in which the anemia prevalence 
ranges from 21-33%, the prevalence in TaHeF was quite high, especially considering the 
about two decades higher age in such populations and that the prevalence of acute heart fail-
ure at study recruitment was higher in these countries41,42,61. This may possibly be explained 
by high renal dysfunction and severity of heart failure, although these factors alone do not 
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seem to explain this large discrepancy in anemia prevalence. Like many other developing 
economies, Tanzania has a high prevalence of anemia among adults in the general population 
and	thus	the	current	findings	maybe	a	reflection	of	this	overall	population	structure	in	which	
the prevalence is 48%125.	Managing	anemia,	and	in	particular,	iron	deficiency,	would	also	be	
of potential interest in attempts to improve symptoms prognosis in heart failure, provided 
that	the	beneficial	effects	of	iron	demonstrated	in	western	countries52,87 are also applicable to 
patients with heart failure in Sub-Saharan Africa.
In	contrast,	other	comorbidities	such	as	diabetes,	ischemic	heart	disease	and	atrial	fibrillation	
were	less	common	in	TaHeF,	as	expected,	as	they	presently	reflect	risk	factors	and	disease	
patterns	dominating	in	developed	countries	and	with	higher	age.	These	findings	may	also	be	
due to a relatively higher population prevalence of diabetes in Europe (9.6%)126 and the USA 
(9.3%)127 than in Tanzania (3.5%)128. 
HIV and Tuberculosis were found to be unique comorbidities seen in TaHeF, not being re-
ported from most of the heart failure or cardiomyopathy cohorts in developed countries13,14,129 
but mentioned in some130.	This	pattern	might	be	a	true	reflection	of	the	population	difference	
in which the prevalence of HIV in Africa is 4.4%, much higher than in Europe (0.4%)131. 
The contribution of HIV cardiomyopathy and TB pericarditis to the presumed cause of heart 
failure	in	about	3%	of	patients	in	TaHeF	reflects	the	continuing	impact	of	these	conditions	in	
Sub-Saharan Africa. The two conditions affect each other and HIV is associated with poor 
prognosis in heart failure130,132.
Therapy
Regardless of underlying etiology, the heart failure syndrome is driven by compensatory 
but maladaptive neurohormonal activation. The neurohormonal hypothesis and the evidence 
based practice that evolved from randomized trials of neurohormonal antagonists represents 
a major advance in clinical medicine in general and heart failure in particular. Clinical trials 
such as Studies of Left Ventricular Dysfunction (SOLVD), the Metoprolol CR/XL Randomised 
Intervention	 Trial	 in-Congestive	 heart	 failure	 (MERIT-HF),	 the	 Cardiac	 Insufficiency	
Bisoprolol Study II (CIBIS-II) trial, Randomized Aldactone Evaluation Study (RALES) and 
the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study23,24,133,134 
have established ACE-inhibitors, angiotensin receptor blockers, mineralocorticoid receptor 
antagonists and beta-blockers as cornerstones in the treatment of heart failure with reduced 
ejection in developed countries. Fundamental heart failure therapy in the form of renin-
angiotensin system inhibition (angiotensin-converting-enzyme inhibitor or angiotensin 
receptor blocker) was highly utilized in both TaHeF and SwedeHF, and spironolactone was 
used extensively in TaHeF. In fact, given the mild but worse renal function in TaHeF (median 
creatinine clearance 69 ml/min in this cohort, compared to 93 ml/min in the age and sex 
matched Swedish cohort), the use of RAS-antagonists was notably high but comparable to 
other cohorts in Sub-Saharan Africa20,34. The high use of RAS-antagonists in TaHeF might 
be	related	to	the	belief	that	its	survival	benefit	can	be	extended	in	even	in	those	patients	with	
heart failure and mild renal dysfunction.  Indeed, data from the Heart Outcomes Prevention 
Evaluation (HOPE) study, the Losartan Intervention for Endpoint Reduction in Hypertension 
(LIFE) Trial and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart 
Attack	 Trial	 (ALLHAT)	 studies	 have	 confirmed	 the	 benefit	 of	 angiotensin-converting-
enzyme inhibitor use also in mild chronic kidney disease135–138. The current patterns of use 
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of	these	drugs	in	TaHeF	may	be	a	reflection	of	improved	adherence	to	guideline	based	heart	
failure therapy.
Despite	 these	 important	 practices,	 there	 is	 a	 need	 for	 additional	 studies	 on	 the	 efficacy	
of therapies for heart failure in black patients particularly in Sub-Saharan Africa due to 
reported lesser response to angiotensin-converting-enzyme inhibitor as compared to white 
patients139,140.	The	findings	from	the		African	American	Heart	Failure	(A-HEFT)	trial141 that 
addition	of	a	fixed	dose	of	isosorbide	dinitrate	plus	hydralazine	to	standard	therapy	for	heart	
failure resulted in a better composite score made up of weighted values for death from any 
cause,	a	first	hospitalization	for	heart	failure,	and	change	in	the	quality	of	life	specifically	
among black patients with advanced heart failure should be further investigated in Sub-
Saharan Africa trials.
In	contrast,	 the	 low	use	of	beta-blockers	 in	TaHeF	 is	 concerning,	 and	may	 reflect	 fear	of	
worsening heart failure in patients with an already advanced heart failure syndrome (higher 
NYHA class). Digoxin and nitrates are readily available drugs historically used extensively 
in	heart	failure,	and	their	greater	use	in	TaHeF	may	reflect	slower	adoption	of	contemporary	
heart failure management.
Despite	 a	 not	 negligible	 16%	 prevalence	 of	 atrial	 fibrillation	 in	 TaHeF,	 the	 use	 of	 oral	
anticoagulants	was	 low,	which	 is	concerning	with	 this	arrhythmia	already	 identified	as	an	
important risk marker of poor prognosis in heart failure. The 4% usage of warfarin in this 
population is low compared to in developed countries but also far below the 16% utilization 
reported from nine African countries as part of the Registry on variations in etiology and 
management	of	atrial	fibrillation	in	a	prospective	(RE-LY	AF)	study142. This disparity might 
have resulted from the fact that the RE-LY AF included patients presenting in an emergency 
setting, suggesting a high-risk group, which could have prompted greater attention to 
indications for warfarin therapy, as well as the quality of care in RE-LY registry likely being 
positively affected by its connection with the trial itself.
With limited access to blood sampling for adjustment of warfarin-based anticoagulation and 
newer	oral	anti-coagulants	 remaining	patented	and	expensive,	atrial	fibrillation,	driven	by	
hypertension and common in heart failure may indeed emerge as an important public health 
problem in Sub-Saharan Africa countries, whether in the presence or absence of heart failure. 
According to CHA2DS2-VASc score, heart failure provides one point, in itself resulting in an 
annual ischemic stroke of 0.6% risk of ischemic stroke in untreated patients143, and heart failure 
frequently coexists with hypertension, higher age, and vascular disease, providing additional 
points and clear indications for oral anti-coagulation. Indeed, with anticoagulation the risk 
of ischemic stroke (and other embolic events) is reduced by about two-thirds irrespective 
of baseline risk144,145. Thus ambitious public health interventions are required in Tanzania to 
reduces this risk by possibly providing continuing medical education to physicians, supply 
of anticoagulants, monitoring kits and adherence to the available treatment guidelines146,147.
Despite	a	lack	of	efficacy	evidence	there	was	considerable	use	of	most	heart	failure	drugs	
also in heart failure preserved	fraction	 in	both	TaHeF	and	SwedeHF.	This	may	reflect	 the	
use of these drugs for hypertension or a perception that they may be effective in heart failure 
reduced ejection fraction.
Abel Makubi
40
Prognosis
After age and gender matching, the TaHeF patients had more than twice the crude risk of 
death	 compared	 to	 those	 in	SwedeHF.	As	 this	 greatly	 reflected	more	 severe	NYHA	class	
and impaired renal function, and probably to some extent, less use of some evidence based 
heart	failure	drugs,	there	was	no	significant	remaining	difference	in	risk	after	multivariable	
adjustment. The few previous studies comparing heart failure in Sub-Saharan Africa vs. 
developed countries did not match patients or perform patient-level comparisons, nor 
did they perform adjustments for important confounders11,21,148.	 Our	 findings	 suggest	 that	
previous	data	reflect	a	combination	of	younger	age	but	greater	severity	of	heart	failure	and	
less well developed treatment in Sub-Saharan Africa countries, with potentially opposite and 
balancing effects on outcomes. 
Previous observations of similar prognosis in heart failure preserved vs. reduced ejection 
fraction149,150	 were	 echoed	 in	 our	 study,	 which	 to	 the	 best	 of	 our	 knowledge	 is	 the	 first	
comparison of heart failure preserved vs. reduced ejection fraction in Sub-Saharan Africa 
and developed countries. Other studies, in particular clinical trials with selected and less 
representative patient populations, reported lower mortality in heart failure preserved ejection 
fraction110,151.
Analysis of predictors of mortality in the TaHeF and SwedeHF populations revealed that 
the main predictors were similar. Exceptions were the lack of prediction by plasma sodium 
levels and of an association between the use of renin-angiotensin system antagonist and beta-
blockers and outcomes. Although some of the predictors are similar to in THESUS-HF132, 
further exploration is needed, as the limited number of events in TaHeF may cause a type 2 
statistical error.
Iron deficiency prevalence and association with prognosis in heart failure
A	 specific	 and	 highly	 relevant	 comorbidity	 in	 heart	 failure	 is	 iron	 deficiency,	 which	 is	
common and associated with increased risk whether associated with anemia or not. Iron 
deficiency	was	 examined	 in	 studies	 II	 and	 IV.	The	 overall	 prevalence	 of	 iron	 deficiency	
regardless	of	anemia	was	49%.	This	is	comparable	to	findings	reported	from	pooled	analyses	
from developed countries77. The prevalence was higher in the TaHeF population than the 
22% and 37% reported in some studies74,89, but lower than reported in others61,75,76 in which 
iron	deficiency	was	seen	in	58-73%.
Data	on	 the	epidemiology	and	pathophysiology	of	 iron	deficiency	 in	heart	 failure	 in	Sub-
Saharan	Africa	are	 scarce.	The	variations	 in	 iron	deficiency	prevalence	seen	 in	 the	above	
studies	 might	 relate	 to	 a	 lack	 of	 standard	 definitions	 for	 iron	 deficiency	 in	 heart	 failure	
and differences in the characteristics of the studied populations. Underlying malnutrition 
and chronic infections, less commonly seen in developed countries, are other potential 
contributors in developing countries.
The	relation	between	iron	deficiency,	anemia	and	heart	failure	has	been	explored	in	developed	
countries89.	Recent	 reports	 indicate	 that	 iron	deficiency	 is	associated	with	a	compromised	
prognosis in heart failure, which is independent of anemia77,89. Considerably less is known 
about	the	role	of	iron	deficiency	and	anemia	in	heart	failure	populations	from	Sub-Saharan	
Africa50.
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There	are	limited	data	reporting	the	impact	of	iron	deficiency	on	prognosis	in	heart	failure.	
There	are	conflicting	findings	though	poor	outcome	appears	to	be	the	predominant	finding.	
In most available studies74,76,77,89,	 iron	deficiency	carried	a	higher	 risk	of	poor	outcome	 in	
heart failure irrespective of the presence of anemia. In contrast, Parikh et al75 found that 
iron	deficiency	did	not	relate	to	all	cause	or	cardiovascular	mortality	in	patients	with	self-
reported	heart	failure.	The	present	data	show	that	iron	deficiency	anemia	but	not	anemia	or	
iron	deficiency	alone	was	an	independent	predictor	of	poor	outcomes	in	heart	failure.	Four	
statistical	models	were	analyzed	taking	into	consideration	both	iron	deficiency	and	anemia	
and including both patients with heart failure preserved and reduced ejection fraction. It 
appeared	that	not	only	anemia	or	iron	deficiency	alone	but	more	importantly	iron	deficiency	
anemia was associated with the worst prognosis in heart failure. Further studies in heart 
failure are needed to explain the prognostic variations and levels of impact contributed by 
each	of	iron	deficiency,	iron	deficiency	and	anemia	alone	and	in	combination.
Iron therapy in heart failure
Study	 IV	 demonstrated	 for	 the	 first	 time	 that	 oral	 iron	 improves	 serum	 ferritin	 levels	 in	
patients	with	heart	failure	and	iron	deficiency	in	a	prospective	study	design	setting.	Serum	
ferritin more than doubled after the administration of oral iron during 90 days in patients with 
heart failure, providing evidence of a preserved or at least adequate bioavailability of oral iron 
in such populations. That oral iron is able to increase ferritin levels suggests that it has been 
absorbed through the gastrointestinal tract. Thus the purported inhibition of oral absorption 
by hepcidin modulation at the gastrointestinal level remains controversial, particularly in 
patients with heart failure51,62.
The magnitude of the incremental increase in ferritin in the current study was slightly higher 
than the 98% reported by Niehaus et al. in retrospective study of 105 patients with heart 
failure reduced ejection fraction106. This may at least partially be explained by different study 
designs (retrospective vs. prospective) allowing a closer monitoring of adherence in the 
current study. In comparison to randomized trials which applied oral iron in one of their arms, 
a	serum	ferritin	incremental	increase	was	consistent	in	the	present	study	with	the	findings	
reported by Beck-da Silva et al107 in the oral iron arm and better than in Parissis et al152. 
The	possibility	to	compare	the	present	findings	with	studies	administering	iron	intravenously	
in patients with heart failure96,97 is limited due to substantial methodological differences. 
Findings in the i.v. iron arm of the FAIR-HF86 appear similar to the current data. Thus, study 
IV suggests that iron stores may be recovered with oral iron to a similar extent as with i.v. 
iron.	 If	confirmed	 these	findings	may	have	considerable	beneficial	 logistical	and	practical	
implications.
Previous studies in heart failure have not shown an improvement in exercise capacity with 
oral iron152–154, whereas one small study in cyanotic congenital heart disease has155. The present 
improvement in 6MWT, +31meters or 6% after 90 days of oral iron, is comparable to the +30-
40 meters compared to placebo by i.v. iron in the Ferinject Assessment in Patients with IRon 
deficiency	and	chronic	Heart	Failure	 (FAIR-HF)86 and Ferric CarboxymaltOse evaluatioN 
on	perFormance	in	patients	with	IRon	deficiency	in	coMbination	with	chronic	heart	failure	
(CONFIRM-HF)86,87. A major appeal of i.v. iron is the large and consistent improvement 
in peak VO288, as well as 6MWT distance, NYHA class, and quality of life measured by 
EQ-5D and the Kansas City Cardiomyopathy Questionnaire (KCCQ)52,87. However, the 
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costs and logistical challenges of i.v. iron treatment in large heart failure populations may 
complicate its implementation particularly in countries with limited health care resources. 
Thus oral iron should be extensively studied particularly in Sub-Saharan Africa, where both 
the	resources	of	i.v.	iron	and	the	pathophysiology	of	iron	deficiency	may	be	different	from	
that	in	developed	countries.	Although	study	IV	provided	distinctly	positive	findings,	due	to	
absent randomization it is not possible to rule out a placebo effect, particularly on the 6MWT. 
Therefore,	it	is	important	to	verify	the	present	findings	in	a	randomized	trial.
Limitations of the studies presented in this thesis
The TaHeF study was conducted in a developing country where resources for recruitment, 
diagnosis, monitoring of patients and embarking on clinical trials are limited. If further 
patients could have been recruited it would have contributed to more events. By similar 
reasons,	a	non-randomized	clinical	trial	(study	IV)	was	the	first	feasible	step	prior	to	more	
complex and expensive randomized trials.
Policy implications and considerations
•	 The	findings	 in	 Studies	 I-IV	 are	 highly	 clinically	 and	 socially	 relevant.	They	may	 be	
addressed with quite simple and inexpensive measures.
o Hypertension emerged to be a predominant contemporary cause of heart failure in Sub-
Saharan	Africa.	Hypertension	is	easy	to	diagnose	and	treat.	The	findings	in	this	thesis	
thus call for concerted policy efforts to improve awareness of hypertension and access 
to diagnosis and therapy on a population level.
o Anemia,	 iron	 deficiency,	 atrial	 fibrillation,	 and	 lower	 education	 level	 adversely	
impacted the prognosis of heart failure. In this context, the underutilization of oral 
anti-coagulation	 in	 Tanzania	 in	 the	 setting	 of	 heart	 failure	 and	 atrial	 fibrillation	 is	
concerning and highlights the need for improved access to oral anti-coagulation 
therapy	 and	 monitoring.	 Novel	 approaches	 to	 treating	 anemia	 and	 iron	 deficiency,	
such as potentially oral iron, are needed. Broadening access to education may improve 
health literacy and health outcomes in general. 
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CONCLUSIONS
Patients with heart failure in Tanzania are younger than in developed countries but the 
etiologies are becoming more similar, with hypertension becoming more and rheumatic 
heart disease less important. Even after age and gender matching (vs. heart failure patients 
in Sweden), patients in Tanzania had more severe heart failure despite higher LVEF, and 
worse crude but similar adjusted prognosis. Hypertension was a common risk factor and 
underlying etiology and is possible to screen for and treat. Predictors of mortality possible to 
intervene	against	were	anemia,	atrial	fibrillation	and	lack	of	education.	Iron	deficiency	was	
common in heart failure patients in Tanzania and was independently associated with the risk 
for heart failure hospitalization or death. Oral	iron	supplementation	was	sufficiently	absorbed	
to replenish iron stores in Sub-Saharan patients with heart failure and resulted in improved 
hemoglobin, 6MWT distance, LVEF and NT-proBNP.
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